Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is relat...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-07, Vol.8 (8), p.889-906
Main Authors: Kuhn, Chantal, Weiner, Howard L
Format: Article
Language:English
Subjects:
Animal models
Antigens
Apoptosis
Arthritis
Autoimmune diseases
CD3 antigen
Clinical trials
Cytokines
Dendritic cells
Diabetes
Disease
Endocrinology
foralumab
Genetic engineering
immune tolerance
Immunoglobulins
Immunological tolerance
Immunotherapy
Intravenous administration
Lymphocytes
Monoclonal antibodies
monoclonal CD3 antibodies
Mucosa
otelixizumab
teplizumab
Transplants & implants
Tregs
Tumor necrosis factor-TNF
Type 1 diabetes
visilizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2016-0049